Anti-guanosine antibody as a molecular delivery vehicle

Patent metadata

Field	Value
Publication number	US-12486318-B2
Application number	US-201716310326-A
Country	US
Kind code	B2
Filing date	Jun 15, 2017
Priority date	Jun 15, 2016
Publication date	Dec 2, 2025
Grant date	Dec 2, 2025

Abstract

Guanosine-targeted nanocarriers for encapsulating an active agent and delivering it to extracellular guanosine and DNA are provided. The nanocarriers, for example, polymeric particles, liposomes, and multilamellar vesicles have targeting moiety that targets guanosine attached, linked, or conjugated thereto. The targeting moiety that targets guanosine is typically an antibody, or variant, fragment, or fusion protein derived therefrom that binds to guanosine. The targeting moiety can be a circulating autoantibody that binds guanosine such as those commonly found in patients with SLE. Cytoplasmic delivery vehicles that do not localize into endosomes or lysosomes are also provided. The delivery agent is typically an antibody, or variant, fragment, or fusion protein derived therefrom that binds to guanosine. In some embodiments, the targeting moiety or delivery agent is antibody 4H2 or a variant, fragment, or fusion protein derived therefrom. Pharmaceutical compositions, methods of use, and dosage regimens are also provided.

First claim

We claim:

1 . A nanocarrier comprising a nanoparticle comprising a targeting moiety conjugated or linked to the outer surface thereof and a cytotoxic agent encapsulated therein,
wherein the targeting moiety consists of an effective amount of a plurality of molecules of an antibody that binds to extracellular guanosine to increase localization of the nanocarrier to extracellular guanosine relative to the same nanocarrier in the absence of the targeting moiety, wherein the nanocarrier is free from unconjugated antibody, and wherein the nanocarrier creates a positive feedback loop that stimulates increased localization of the nanocarrier to the extracellular guanosine over time in vivo when administered to subject.

2 . The nanocarrier of claim 1 , wherein the antibody is an intact immunoglobulin, or a mono-, di-, or tri-valent or multivalent single chain variable fragment (scFv), an Fab, F(ab′) 2 , minibody, scFv-Fc, diabody, triabody, or tetrabody derived therefrom that comprises the complementarity-determining regions of the intact immunoglobulin and binds to guanosine.

3 . The nanocarrier of claim 1 , wherein the antibody comprises a heavy chain comprising the three complementarity-determining regions (CDR) of SEQ ID NO:5, and a light chain comprising the three CDR of SEQ ID NO:1.

4 . The nanocarrier of claim 3 , wherein the antibody is a mono-, di-, or tri-valent or multivalent single chain variable fragment (scFv), an Fab, F(ab′) 2 , minibody, scFv-Fc, diabody, triabody, or tetrabody.

5 . The nanocarrier of claim 1 , wherein the antibody comprises
(i) a heavy chain comprising the three complementarity-determining regions (CDR) of SEQ ID NO:5, and a light chain comprising the three CDR of SEQ ID NO:1; or (ii) a heavy chain comprising the amino acid sequence from SEQ ID NO: 5, and a light chain comprising the amino acid sequence of SEQ ID NO:1; or (iii) the scFv of SEQ ID NO:22.

6 . The nanocarrier of claim 1 , wherein the nanoparticle is selected from the group consisting of polymeric nanoparticle, liposome, and multilamellar vesicle.

7 . The nanocarrier of claim 6 , wherein the nanoparticle is a polymeric nanoparticle.

8 . The nanocarrier of claim 1 , further comprising one or more active agents encapsulated therein.

9 . A pharmaceutical composition comprising an effective amount of the nanocarrier of claim 1 .

10 . A method of detecting site or sites of cancer, tissue damage, injury, or ischemia comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 9 , wherein the one or more active agents is an agent that is detectable using diagnostic imaging or nuclear medicine techniques.

11 . A cytoplasmic molecular delivery vehicle consisting of an antibody that binds guanosine comprising a heavy chain comprising the three complementarity-determining regions (CDR) of SEQ ID NO:5, and a light chain comprising the three CDR of SEQ ID NO: 1 linked to a cargo,
wherein the delivery vehicle can deliver the cargo into the cytoplasm of cells and avoid localization to endosomes or lysosomes.

12 . The delivery vehicle of claim 11 , wherein the antibody is a mono-, di-, or tri-valent or multivalent single chain variable fragment (scFv), an Fab, F(ab′) 2 , minibody, scFv-Fc, diabody, triabody, or tetrabody.

13 . A pharmaceutical composition comprising an effective amount of the delivery vehicle of claim 11 .

14 . A method of detecting site or sites of cancer, tissue damage, injury, or ischemia comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 13 , wherein the cargo is an agent that is detectable using diagnostic imaging or nuclear medicine techniques.

15 . A single chain variable fragment comprising the amino acid sequence of SEQ ID NO:22.

16 . The nanocarrier of claim 8 , wherein the cytotoxic agent is a chemotherapeutic agent.

17 . The nanocarrier of claim 8 , wherein the cytotoxic agent is a radiosensitizer.

18 . The nanocarrier of claim 5 , wherein the nanocarrier can cross the blood-brain-barrier (BBB) following systemic administration to a mammalian subject.

19 . A polymeric nanoparticle comprising poly(lactic-co-glycolic acid)-poly(ε-carbobenzoxyl-L-lysine) (PLGA-PLL) and an antibody comprising a heavy chain comprising the three complementarity-determining regions (CDR) of SEQ ID NO:5, and a light chain comprising the three CDR of SEQ ID NO:1 conjugated to PLL and displayed on the exterior of the nanoparticle.

20 . The polymeric nanoparticle of claim 19 comprising an active agent encapsulated therein.

Assignees

• Univ Yale

Inventors

• Hansen James
• Zhou Jiangbing

Classifications

• C07K2317/626

  Diabody or triabody · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/569

  Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title